Tirzepatide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tirzepatide
DrugBank Accession Number
DB15171
Background

Tirzepatide is under investigation in clinical trial NCT03311724 (A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes).

Type
Biotech
Groups
Investigational
Synonyms
  • Tirzepatide
External IDs
  • LY3298176

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Tirzepatide.
AcebutololThe therapeutic efficacy of Tirzepatide can be increased when used in combination with Acebutolol.
AcetazolamideThe therapeutic efficacy of Tirzepatide can be increased when used in combination with Acetazolamide.
AcetohexamideThe risk or severity of hypoglycemia can be increased when Acetohexamide is combined with Tirzepatide.
Acetyl sulfisoxazoleThe therapeutic efficacy of Tirzepatide can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Tirzepatide.
AlbiglutideThe risk or severity of hypoglycemia can be increased when Albiglutide is combined with Tirzepatide.
AlclometasoneThe risk or severity of hyperglycemia can be increased when Alclometasone is combined with Tirzepatide.
AlogliptinThe risk or severity of hypoglycemia can be increased when Alogliptin is combined with Tirzepatide.
AmcinonideThe risk or severity of hyperglycemia can be increased when Amcinonide is combined with Tirzepatide.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
OYN3CCI6QE
CAS number
2023788-19-2

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentBMI >27 kg/m2 / Obesity (Disorder)3
3Active Not RecruitingTreatmentType 2 Diabetes Mellitus1
3CompletedTreatmentType 2 Diabetes Mellitus7
3RecruitingTreatmentBMI >27 kg/m2 / Metabolic and Nutritional Disorders / Obesity (Disorder)1
3RecruitingTreatmentBMI >27 kg/m2 / Obesity (Disorder) / Type 2 Diabetes Mellitus1
3RecruitingTreatmentHeart Failure With Preserved Ejection Fraction (HFpEF) / Obesity (Disorder)1
3RecruitingTreatmentObesity (Disorder)1
3RecruitingTreatmentType 2 Diabetes Mellitus2
2CompletedTreatmentType 2 Diabetes Mellitus2
2RecruitingTreatmentNon Alcoholic Steatohepatitis (NASH)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 14:55 / Updated on February 21, 2021 18:55